Evolution of the Average Target: Supernus Pharmaceuticals, Inc.

Evolution of the Target Price: Supernus Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Supernus Pharmaceuticals, Inc.

8e2aa7d85e7362fd720.soIUbzVFfuka3H1M8fd-OOahx4EW5w0YAWwDA3W2goQ.0dddXxgoTtlSr00Ap5IpCtXSlMd7sVJBZRVIdz3V5fOLynBfAxMusX2eFg~36b7af8494ce6c12d996a027c4c4e6fc
01-07 Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says MT
29/10/25 BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target MT
09/10/25 Supernus Pharmaceuticals Shares Rise After Piper Sandler Upgrade MT
09/10/25 Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $65 From $40 MT
30/07/25 Supernus Shares Rise After Upgrade From Cantor Fitzgerald MT
30/07/25 Cantor Fitzgerald Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $42 From $36 MT
16/06/25 Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral MT
19/02/25 Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57 MT
06/01/25 Cantor Fitzgerald Initiates Supernus Pharmaceuticals at Overweight With $57 Price Target MT
28/02/24 Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating MT
10/05/23 Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $46 From $45, Keeps Overweight Rating MT
23/01/23 Piper Sandler Adjusts Supernus Pharmaceuticals Price Target to $47 From $40, Maintains Overweight Rating MT
31/08/22 Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $38 From $33, Reiterates Overweight Rating MT
01/12/21 Jefferies Reinstates Supernus Pharmaceuticals at Buy With $44 Price Target MT
13/04/21 Supernus Pharmaceuticals : Jefferies Lifts Supernus Pharmaceuticals to Buy From Hold, Price Target to $40 From $25 MT
03/02/21 Supernus Pharmaceuticals : Piper Sandler Adjusts Supernus Pharmaceuticals PT to $35 From $30, Maintains Overweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+41.86%
-0.55%
+12.99%
-9.65%
-4.31%
+49.54%
+47.56%
- - -18.03%
Average +14.93%
Weighted average by Cap. +2.20%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
43.53USD
Average target price
61.75USD
Spread / Average Target
+41.86%
High Price Target
67.00USD
Spread / Highest target
+53.92%
Low Price Target
55.00USD
Spread / Lowest Target
+26.35%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. SUPN Stock
  4. Consensus Supernus Pharmaceuticals, Inc.